Device Trial Radar · NCT06886191
puO2 in RenalGuard Pilot Study
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 17, 2025
Primary completion
Jun 12, 2026
Study completion Jun 15, 2026
Sponsor
- Lead sponsor
- Sahlgrenska University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 20, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The PuO2 in RenalGuard (PURE) study is planned as a single center, randomized controlled pilot study comparing renal oxygenation during cardiac surgery with cardiopulmonary bypass (CPB) with or without balanced forced diuresis using the RenalGuard (RG) system. Renal oxygenation will be assessed by urine oxygen tension, continuously measured by optodes placed through the urine catheter. Measurements will start after induction of anesthesia and continue for 24 hours. In total, 30 patients will be randomized 1:1 to RG or standard of care (SOC) during cardiac surgery with CPB. In the RG group, the forced diuresis with neutral fluid balance will be maintained from before the start of surgery until 3 hours after weaning from CPB. The primary endpoint is the group difference (RG vs SOC) in delta PuO2, defined as the change in mean PuO2 from baseline to the last 5-minute period at 45 minutes after start of CPB. The secondary endpoints include 1. Group difference in mean PuO2 before, during and after CPB 2. Group difference in time weighted area under the curve for PuO2 3. Group differences in renal near infrared spectroscopy (NIRS) before, during and after CPB 4. Group difference in urine and blood biochemistry including renal biomarkers 5. Group difference in urine output and fluid balance during surgery and first postoperative day 6. Group differences in postoperative AKI according to the KDIGO criteria 7. Time (minutes) with puO2 ≤ 15 and ≤ 10 mmHg during and after CPB 8. Dynamics of PuO2 during the early postoperative phase Patients ≥18 years scheduled for cardiac surgery with CPB with estimated glomerular filtration rate ≥50 ml/min are eligible for inclusion. Exclusion criteria include patients on higher doses of furosemide, patients with AKI or under renal replacement therapy. Patients will be analyzed according to study group. In patients where hemofiltration has been used during CPB, control group patients who has received furosemide and patients in the RG group who do not reach target urine flow will be excluded from the main analysis but will be included in a separate analysis.
Conditions
- Cardiac Surgery Subjects
Interventions
RenalGuard TherapyDevice
Fluid management system, which weighs urine and controls intravenous administration of crystalloid solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Delta PuO2Time frame: Baseline (before start of surgery) to 45 minutes after start of CPB
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Cardiothoracic Anesthesia and Intensive Care, Sahlgrenska University Hospital
Gothenburg, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.